🌍 Pharmidex Announces Strategic Collaboration with SMC Laboratories, Japan

We are delighted to announce our new strategic collaboration with SMC Laboratories, Inc., strengthening our international partnerships and creating new opportunities to support pharmaceutical and biotechnology companies worldwide. At Pharmidex, we provide comprehensive preclinical drug discovery and development services, supporting our clients from early-stage discovery through to regulatory development. Our established capabilities span: 🔬 Early-stage screening, in vitro ADME and DMPK 🧪 In vivo pharmacology, PK/PD and therapeutic area expertise spanning CNS, respiratory research, oncology and other disease areas 📊 LC-MS/MS bioanalysis and translational biomarker analysis 🔬 Histology, pathology and advanced analytical techniques 🧬 Discovery and GLP toxicology, safety assessment and GLP/GCP bioanalysis Through this collaboration, we are bringing together Pharmidex's broad preclinical expertise with SMC Laboratories' specialist disease-model capabilities, particularly in MASH, liver disease and fibrosis. Together, we aim to support more integrated preclinical research programmes, broaden scientific opportunities and provide our clients with greater flexibility throughout the drug development process. This partnership also represents an important step in expanding our international presence and strengthening scientific and commercial relationships across the UK, Europe, Japan and beyond. We look forward to working closely with the SMC Laboratories team, exploring new opportunities and continuing to support innovative drug discovery and development programmes worldwide.